

Aung Naing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/480491/publications.pdf>

Version: 2024-02-01

28
papers

1,899
citations

759233

12
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

2222
citing authors

#	ARTICLE	IF	CITATIONS
1	Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. , 2022, 10, e004089.		50
2	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
3	Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Supportive Care in Cancer, 2021, 29, 2305-2317.	2.2	29
4	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	3.4	7
5	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. Cancer, 2021, 127, 391-402.	4.1	6
6	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific Reports, 2021, 11, 3667.	3.3	20
7	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. British Journal of Cancer, 2021, 124, 1533-1539.	6.4	20
8	CX-072 (pacmilimab), a Probody [®] PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
9	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	1.6	121
10	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	1.6	580
11	Letter to the editor from Pant et al. , 2021, 9, e003991.		0
12	Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clinical Cancer Research, 2020, 26, 984-989.	7.0	100
13	T-cell agonists in cancer immunotherapy. , 2020, 8, e000966.		69
14	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	7.0	16
15	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020, 183, 347-362.e24.	28.9	349
16	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume 1—conceptual challenges. , 2020, 8, e001389.		7
17	Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. , 2020, 8, e000870.		21
18	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 6196-6203.	7.0	35

#	ARTICLE	IF	CITATIONS
19	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
20	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
21	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE ₂ -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
22	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Molecular Cancer Therapeutics, 2020, 19, 1165-1172.	4.1	15
23	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
24	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-“PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
25	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1025-1033.	7.0	45
26	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
27	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	3.4	86
28	Being Realistic and Optimistic in Curing Cancer. Journal of Immunotherapy and Precision Oncology, 2018, 1, 53-55.	1.4	21